Ms. Baker was most recently an Executive-in-Residence at Kleiner Perkins Caufield & Byers, which she joined in 2006. Prior to that, she was President of BabyCenter, LLC, a Johnson & Johnson company. Under her leadership, BabyCenter became the world's leading Web site for new and expectant parents, winning numerous online health awards and expanding significantly offline and internationally. Prior to her tenure with BabyCenter and Johnson & Johnson, she was a Senior Vice President at Intuit, Inc., which she joined in 1989 as product manager for Quicken. Ms. Baker led the growth of Quicken into the No. 1 personal finance product in the world, along with international expansion and the launch of Quicken.com. Ms. Baker also held executive or product management positions at Now Software, Migent Software and E.F. Hutton.

Mr. Basta has been CEO of BioForm Medical, Inc., a medical aesthetics company whose core product is Radiesse, an injectable dermal filler, since November 2002. Prior to joining BioForm, Mr. Basta served as President and CEO of Gliatech, Inc. a publicly-traded medical device and drug discovery company, and as Vice President Corporate Development and CFO of Creative BioMolecules, Inc. Mr. Basta also served for two years as a corporate finance associate with Dillon, Read & Co., Inc., an investment bank. Mr. Basta holds a degree in biomedical engineering from The Johns Hopkins University and a Master of Management degree from the Kellogg Graduate School of Management at Northwestern University.

Yves Behar is the founder of the San Francisco design studio, fuseproject. fuseproject¹s focus is on humanistic design, tapping into the ³giving² element of the creative profession, with the goal of creating projects deeply in-tune with the needs of a sustainable future, connected with human emotions, and self-expressive. Most recently, he and his firm have designed the $100 laptop titled One Laptop Per Child, aimed at bringing access to education to the world¹s poorest children. Yves¹ commercial projects, whether it is a small venture or a large corporate program, is studied for its¹ innovation and impact. This is exemplified with projects such as the Herman Miller LEAF Lamp, the Aliph Jawbone and Y Water. Yves¹ work has been the subject of two solo exhibitions and resides in the permanent collections of international museums worldwide, including the MOMA.

Dr. Kevin Driscoll is the Director of Global New Business & Technology Development for Procter & Gamble Pharmaceuticals. He joined P&G in 1986 and has held numerous leadership positions across P&G businesses in Health and Beauty Care, most recently, serving as Director, Pharmaceuticals Discovery Research. In 2006, Dr. Driscoll was appointed to his current role in which he leads P&G Pharmaceuticals’ global efforts to find, evaluate and in-license new pharmaceutical compounds, devices and diagnostics. He also is responsible for the pharmaceutical development pipeline from preclinical through proof of concept. Outside of P&G, Dr. Driscoll has served in numerous advisory roles for the U.S. Environmental Protection Agency; Food & Drug Administration; World Health Organization; and, the National Research Council’s (NRC) Committee on Toxicology.

Steve Dubin is CEO of Martek Biosciences Corporation (Nasdaq: MATK). Martek is a leader in the innovation and development of omega-3 DHA (docosahexaenoic acid) products that promote health and wellness throughout life. Martek produces life'sDHA(TM), a vegetarian source of DHA, for use in foods, infant formula and supplements, and ARA (arachidonic acid), an omega-6 fatty acid, for use in infant formula. Mr. Dubin previously served in a variety of positions with Martek over the fourteen years before his election as CEO in July 2006 including President, CFO, Treasurer, Secretary, General Counsel and Senior VP, Business Development. Mr. Dubin's other experience includes working with and financing a variety of early-stage technology companies.

Robert E. Grant joined Allergan as Corporate Vice President and President of Allergan Medical in June of 2006. Previously he served as a director, Chairman of the Board, President and Chief Executive Officer of BIOLASE Technology, Inc. since October 2004. He joined BIOLASE in 2003 and served as Chief Operating Officer until October 2004. From 2002 to 2003, Mr. Grant served as Executive Vice President and General Manager of the Medical Business of Lumenis in Santa Clara, California. In 2002, he served as Executive Vice President and General Manager of the Surgical and Ophthalmic Business of Lumenis.

Robert E. Grove is a business executive and entrepreneur with over twenty years’ experience in the medical laser industry. Dr. Grove received his Ph.D. from the Massachusetts Institute of Technology, and co-founded Star Medical Technologies in 1993. Star rapidly became the market leader with its line of LightSheer diode laser systems for permanent hair reduction. While at Star, Dr. Grove served on the Board of Directors of the American Society for Lasers Medicine and Surgery. Since January of 2003, Grove has served as CEO of SpectraGenics, Inc., his fourth start-up venture. The company’s mission is to become the global leader in therapeutic, light-based aesthetic devices for the consumer market. Dr. Grove is the author of ten scientific papers in peer-reviewed journals and holds eight U.S. patents in the field of medical lasers and applications.

Chris Hacker, IDSA, is Chief Design Officer, Global Design and Design Strategy at Johnson & Johnson Consumer Group of Companies. He established a global design team based in New York City and is responsible for making design a competitive advantage for Johnson & Johnson. He recently lead the redesign of Rembrandt Toothpaste. His role there is to lead all creative processes for brand identity, packaging design and brand imagery. Chris was Senior VP of Global Marketing and Design for AvedaTM prior to joining Johnson & Johnson. Chris has over 30 years of experience in marketing, product and package design and creative development, having also worked for Warner Bros. Studios, Steuben Glass, Dansk International Design, GAF, JCPenney and Henry Dreyfuss Associates.

Chris is a formally trained industrial designer and received his BS in Industrial Design from the University of Cincinnati. Under his leadership, Aveda was awarded the 2004 National Design Award for Corporate Achievement from the Smithsonian Cooper-Hewitt National Design Museum. His work has also been featured in the Whitney Museum of Art and showcased in Industrial Design magazine.

Mr. Janus is a partner and Director of Research at Palo Alto Investors. Mr. Janus joined the firm in 1997 and specializes in consumer/retail and financial services stocks. Previously Mr. Janus worked for Bank of America, holding positions in finance and product management. Mr. Janus' extensive industry expertise provides him with unique insights into the sectors he covers for Palo Alto Investors. Additionally, in his role as Director of Research, he has been instrumental in building the research team that now consists of ten people, six of whom are analysts. Mr. Janus has an AB in Political Science and an MBA in Finance and Investments, both from U.C. Berkeley. He guest lectures to MBA classes at his alma mater and at other universities as well. Mr. Janus is on the Board of Directors of SV2 (Silicon Valley Social Venture Fund), a group that uses a "venture philanthropy" approach to make grants to nonprofits. He is also on the Board of Advisors for the Community Foundation Silicon Valley

Tad Simons has designed healthcare products for patients for over twenty-six years, and is currently a leader in IDEO's Health & Wellness practice. In his health practice leadership role based in Palo Alto, Tad helps guide a worldwide design practice that accounts for roughly a quarter of IDEO's total business (and reviews nearly a new business opportunity every day). Tad involves himself in project management and client relationship development, and supports a culture where a wide range of human and technical disciplines inform great healthcare solutions.

With experience in physiological measurements, he has worked as a technical designer and leader on many medical projects, including blood pressure systems, oxygen saturation, infusions systems, cardiology products, in vitro diagnostic measurements, and airway gas monitoring for anesthesia. This work has resulted in seventeen US patents.

Prior to joining IDEO, Tad also applied his design, clinical, and business experience to strategic planning for healthcare and life sciences at Hewlett-Packard Laboratories, gathering a broad look at the health industry, world demographics, and the forces that are reshaping the industry today.

Tad has BS and PhD degrees in Mechanical Engineering from Stanford University, and an MS degree from the California Institute of Technology.

Louis Klevan has 30 years of investment banking experience, with a primary focus on acquisition financings, recapitalizations, and direct mezzanine and equity (including PIPEs) transactions. He has completed over 200 private placement transactions, with a significant concentration on the healthcare sector, including biotechnology, specialty pharma and medical devices. Mr. Klevan is Managing Director and Director of the Private Placement Group at BMO Capital Markets, having joined its predecessor firm Gerard Klauer Mattison in 2002. Previously, he was a Director at DLJ/CSFB, responsible for managing private mezzanine and equity transactions. He and his partners grew the firm’s private placement effort into a world class leader. Prior to joining DLJ/CSFB, Mr. Klevan held senior management roles in the private placement groups of several major competitors, including Banc of America Securities, Security Pacific Merchant Bank, and PaineWebber Inc. He began his career at Chemical Bank. Mr. Klevan received his MBA from Carnegie Mellon University and his BA, magna cum laude, from the University of Pittsburgh.

Keith Leonard is President and CEO of Kythera Biopharmaceuticals, Inc., a company focused on bringing breakthrough science to Aesthetic and Medical Dermatology. Keith’s prior experience includes more than 13 years at Amgen including, most recently, Senior Vice President and General Manager of Amgen Europe where he was responsible for all commercial operations in Europe, the Middle East and Africa. Keith was responsible for leading several major groups within Amgen including the U.S. Rheumatology Business, Information Management, Corporate Engineering, European Logistics. He has nine plus years of European business experience. Keith is a member of the Board of Directors of ARYx Inc. based in Fremont, California and Affymax, Inc. based in Palo Alto, California. Keith holds a BS in Engineering from UCLA, a BA in History from the University of Maryland, an MS in Engineering from UC Berkeley, and an MBA from the Anderson School at UCLA.

Dr. McClellan is Senior Fellow, Director of the Engelberg Center for Healthcare Reform, and Leonard D. Schaeffer Director’s Chair in Health Policy Studies at the Brookings Institution. The center is studying ways to provide practical solutions for access, quality, and financing challenges facing the U.S. health care system. He is also a Visiting Fellow at the American Enterprise Institute, Harvard Business School, and the University of Texas.

As both a physician and economist, Dr. McClellan has utilized his dual training at several high level government appointments including administrator of the Center for Medicare and Medicaid Services (2004-2006); commissioner of the U.S. Food and Drug Administration (2002-2004); member of the President’s Council of Economic Advisers and senior director for health care policy for the White House (2001-2002). During the Clinton administration, he was deputy assistant secretary of the Treasury for economic policy (1998-1999). Dr. McClellan was also an associate professor of economics and associate professor of medicine (with tenure) at Stanford University, where he was on leave during his government service. He has twice received the Kenneth J. Arrow Award for Outstanding Research in Health Economics.

Dr. McClellan is a member of the Institute of Medicine of the National Academy of Sciences, a research associate of the National Bureau of Economic Research, and a member of the advisory boards of the American Heart Association and Research!America. A graduate of the University of Texas at Austin, Dr. McClellan earned his M.P.A. from Harvard’s Kennedy School of Government in 1991, his M.D. from the Harvard-MIT Division of Health Sciences and Technology in 1992, and his Ph.D. in economics from MIT in 1993. He completed his residency training in internal medicine at Brigham and Women’s Hospital, Boston. Dr. McClellan has been board-certified in Internal Medicine and has been a practicing internist during his academic career.

Lynne Millheiser Swanbeck is president and CEO of Dynova Labs, a start-up firm financed by Aisling Capital. Dynova Lab’s objective is to enter the natural supplement market with safe and natural herbs and botanicals that have demonstrated efficacy. Lynne joined Dynova from Novartis Pharmaceuticals, where she was Senior Vice President & Region Head for their North American Consumer HealthCare business. Prior to that, Lynne held leadership roles at the Warner- Lambert Company including: General Manager for Southern Europe, Vice President of Retail and Medical Sales and Vice President of Marketing. Lynne began her career at Procter and Gamble in brand management within the package soap and detergent division. She holds a dual degree in biology and management from Syracuse University.